Literature DB >> 17582362

Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches.

Merrilee Needham1, Frank L Mastaglia.   

Abstract

Inclusion body myositis is the most common acquired muscle disease in older individuals, and its prevalence varies among countries and ethnic groups. The aetiology and pathogenesis of sporadic inclusion body myositis are still poorly understood; however genetic factors, ageing, and environmental triggers might all have a role. Unlike other inflammatory myopathies, sporadic inclusion body myositis causes slowly progressing muscular weakness and atrophy, it has a distinctive pattern of muscle involvement, and is unresponsive to conventional forms of immunotherapy. This review covers the clinical presentation, diagnosis, treatment, and the latest information on genetic susceptibility and pathogenesis of sporadic inclusion body myositis.

Entities:  

Mesh:

Year:  2007        PMID: 17582362     DOI: 10.1016/S1474-4422(07)70171-0

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  59 in total

Review 1.  A rare association of early-onset inclusion body myositis, rheumatoid arthritis and autoimmune thyroiditis: a case report and literature review.

Authors:  A M Clerici; G Bono; M L Delodovici; G Azan; G Cafasso; G Micieli
Journal:  Funct Neurol       Date:  2013 Apr-May

Review 2.  Immunotherapy of myositis: issues, concerns and future prospects.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Rheumatol       Date:  2010-02-02       Impact factor: 20.543

3.  Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies.

Authors:  Lisa G Rider; Frederick W Miller
Journal:  JAMA       Date:  2011-01-12       Impact factor: 56.272

4.  GNE variants causing autosomal recessive macrothrombocytopenia without associated muscle wasting.

Authors:  Shoshana Revel-Vilk; Ela Shai; Ernest Turro; Nivin Jahshan; Esti Hi-Am; Galia Spectre; Hagit Daum; Yossef Kalish; Karina Althaus; Andreas Greinacher; Chaim Kaplinsky; Shai Izraeli; Rutendo Mapeta; Sri V V Deevi; Danuta Jarocha; Willem H Ouwehand; Kate Downes; Mortimer Poncz; David Varon; Michele P Lambert
Journal:  Blood       Date:  2018-08-31       Impact factor: 22.113

5.  Increase in number of sporadic inclusion body myositis (sIBM) in Japan.

Authors:  Naoki Suzuki; Masashi Aoki; Madoka Mori-Yoshimura; Yukiko K Hayashi; Ikuya Nonaka; Ichizo Nishino
Journal:  J Neurol       Date:  2011-07-29       Impact factor: 4.849

6.  Knee extensor strength exhibits potential to predict function in sporadic inclusion-body myositis.

Authors:  Linda Pax Lowes; Lindsay Alfano; Laurence Viollet; Xiomara Quintero Rosales; Zarife Sahenk; Brian K Kaspar; K Reed Clark; Kevin M Flanigan; Jerry R Mendell; Michael P McDermott
Journal:  Muscle Nerve       Date:  2012-02       Impact factor: 3.217

7.  Dysphagia in inflammatory myopathy: self-report, incidence, and prevalence.

Authors:  Kylie Patricia Mulcahy; Patricia Claire Langdon; Francis Mastaglia
Journal:  Dysphagia       Date:  2011-03-27       Impact factor: 3.438

8.  Investigation of splicing changes and post-translational processing of LMNA in sporadic inclusion body myositis.

Authors:  Yue-Bei Luo; Chalermchai Mitrpant; Russell Johnsen; Vicki Fabian; Merrilee Needham; Sue Fletcher; Steve D Wilton; Frank L Mastaglia
Journal:  Int J Clin Exp Pathol       Date:  2013-08-15

9.  Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis.

Authors:  Marinos C Dalakas; Goran Rakocevic; Jens Schmidt; Mohammad Salajegheh; Beverly McElroy; Michael O Harris-Love; Joseph A Shrader; Ellen W Levy; James Dambrosia; Robert L Kampen; David A Bruno; Allan D Kirk
Journal:  Brain       Date:  2009-05-19       Impact factor: 13.501

10.  How citation distortions create unfounded authority: analysis of a citation network.

Authors:  Steven A Greenberg
Journal:  BMJ       Date:  2009-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.